oral contraceptive


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to oral contraceptive: oral contraceptive pill

contraceptive

 [kon″trah-sep´tiv]
1. diminishing the likelihood of or preventing conception.
2. an agent that does this; see also contraception.
oral contraceptive a compound, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. See also contraception.

or·al con·tra·cep·tive (OC),

any orally effective preparation designed to prevent conception.

oral contraceptive

n.
Any of various pills containing estrogen and a progestin, or a progestin alone, that inhibit ovulation and are used to prevent conception. Also called birth control pill.

oral contraceptive

Gynecology A preparation of synthetic hormones intended to make a ♀ inconceivable by inhibiting ovulation OC formats Sequential method, combined method. See Biphasic contraceptive, Contraceptives, Monophase contraceptive, Third-generation contraceptive, Triphasic contraceptive.
Oral contraceptives, contraindications
Age–over 35
Breast CA or other estrogen-dependent malignancy
Breast-feeding and < 6 weeks after delivery
Cardiovascular defects–acute MI, ASHD, CVA/TIA
Circulatory defects–varicose veins, phlebitis
Cystic fibrosis
Diabetes and long-term OC use
Hypertension
Liver disease–hepatitis, CA, neoplasms
Migraines
Obesity–BMI > 30
Pregnancy–current, suspected, or recently ended
Sickle-cell disease
Smoking–especially > 1 pack/day

or·al con·tra·cep·tive

(OC) (ōr'ăl kon'tră-sep'tiv)
A medication taken by mouth designed to prevent conception.

oral contraceptive

A drug or combination of drugs taken by mouth for the purpose of preventing pregnancy. Most oral contraceptives must be taken by women. They contain oestrogens and/or PROGESTOGENS and act by preventing the ovaries from producing eggs (ova). They also have some effect in making the lining of the womb less suitable for implantation of the ovum and may make the mucus in the canal of the cervix less easily passable by sperms. Oral contraceptives are second after sterilization in effectiveness in avoiding pregnancy. Risk attributable to oral contraceptives is very small among non-smokers but there are certain categories, notably women with thrombophilia from genetic mutations, in which the risk is slightly increased. The increased risk of breast cancer has been greatly exaggerated. It amounts to no more than roughly 1 additional case per 20,000 women. Also known as ‘the pill’. See also CONTRACEPTION.
References in periodicals archive ?
(20.) Amir, Kiston-Rabin, and Muchnik; Amir and Kiston-Rabin; Higgins and Saxman; Whiteside, Dobbin, and Henry; Kadakia, Carlson, and Sataloff; Rubin, Sataloff, and Korovin; Morris, Gorham-Rowan, and Herring, "The effect of initiating oral contraceptive use on voice"; Morris, Gorham-Rowan, and Herring, "Voice onset time in women as a function of oral contraceptive use on the voice"; F.
Lipid profile in females of reproductive age group using combined oral contraceptive pills.
Oral contraceptives contain synthetic hormones to prevent ovulation by mimicking pregnancy.
The study was conducted in 2010 in Tanzanian drug shops that were accredited to dispense combination oral contraceptives to women after assessing their eligibility.
Oral contraceptive is the only medication associated with developing alveolar osteitis following extraction of teeth.
Ethinyl estradiol is the most frequently used estrogen in combined oral contraceptive pills in a dose range from 20-35 (Mu)g.
2010;59:322-329) provided useful resources, but there were errors in the list of medications cited among those that decrease the efficacy of oral contraceptives in Table 2 on page 327.
This is Glenmark s third female hormonal product approval and it is the second approval for an oral contraceptive. The company received approval in April 2010 for Heather tablets, their generic version of Watson s Nor-QD tablets and the received approval for Norethindrone Acetate 5mg tablets on Thursday.
A Danish study, published in the British Medical Journal, suggests that the risk of thromboembolism in users of the oral contraceptive pill decreases with increasing duration of use and with decreasing oestrogen doses.
The dedicated space for oral contraceptive production fulfills a regulatory requirement needed to sell these products in many countries.